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Abstract
Visceral leishmaniasis (VL) is a neglected tropical disease that affects the poorest com-
munities and can cause substantial morbidity and mortality. Visceral leishmaniasis is char-
acterized by the presence of Leishmania parasites in the spleen, liver and bone marrow,
hepatosplenomegaly, pancytopenia, prolonged fever, systemic inflammation and low body
mass index (BMI). The factors impacting on the severity of VL are poorly characterized.
Here we performed a cross-sectional study to assess whether co-infection of VL patients
with intestinal parasites influences disease severity, assessed with clinical and haematologi-
cal data, inflammation, cytokine profiles and BMI. Data from VL patients was similar to VL
patients co-infected with intestinal parasites, suggesting that co-infection of VL patients with
intestinal parasites does not alter disease severity.
Author summary
Visceral leishmaniasis (VL), a disease caused by a parasite, Leishmania, belongs to the
most neglected tropical diseases: they mainly occur in low-income countries and affect
the poorest populations. The parasites are transmitted via the bite of an insect vector and
migrate to the internal organs. When VL occurs, the patients will present with enlarged
spleen and liver, a disturbed haematological profile with low blood cell counts, systemic
inflammation and malnutrition. This stage of the disease is fatal if left untreated. The fac-
tors that influence VL disease severity are poorly characterized. Here, we recruited
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patients with VL in an area of Ethiopia with a high prevalence of intestinal parasites. Our
aim was to assess whether the disease was more severe in VL patients co-infected with
intestinal parasites. Our results show that clinical and haematological data, inflammation,
cytokine profile and nutritional status of VL patients are similar in VL patients and in VL
patients co-infected with intestinal parasites. These results suggest that co-infection of VL
patients with intestinal parasites does not impact on disease severity.
Introduction
The leishmaniases are a group of neglected tropical diseases (NTDs), largely affecting the least
developed regions of the world. There is an estimated 350 million people in 98 countries at risk
of leishmaniasis [1, 2]. Leishmaniases are a spectrum of diseases: presentations vary from sub-
clinical infection through a range of dermal presentations of varying severity (cutaneous leish-
maniasis, CL) to visceral leishmaniasis (VL). VL is caused by Leishmania (L.) donovani or L.
infantum and is the most severe form of the disease. An estimated 200,000 to 400,000 new cases
of VL with an incidence of 50,000 deaths occur each year, however these numbers are widely
acknowledged to be a gross underestimation of the real burden [3, 4]. In global estimates,
Sudan, South Sudan, Ethiopia, Kenya and Somalia account for the second largest number of
annual VL cases, after South Asia [3]. VL inflicts an immense toll on the developing world and
impedes economic development, with an estimated loss of 2.3 million disability-adjusted life
years. There is no effective vaccine; currently used chemotherapy is toxic and increasing drug
resistance is reported [5]. Infection with Leishmania parasites can be asymptomatic or can man-
ifest as a progressive disease. VL is characterised by hepatosplenomegaly, fever, weight loss,
hyperglobulinemia and pancytopenia [6]; if left untreated, it is almost always fatal. In Ethiopia,
VL is caused by L. donovani and it is one of the most significant vector-borne diseases; Ethiopia
has the second largest number of VL cases in sub-Saharan Africa with an estimated annual bur-
den of 4500 to 5000 new cases. VL is worsened by malnutrition and HIV co-infection, and it has
been suggested that intestinal parasitic infections might also impact on disease severity by mod-
ulating cell-mediated immunity and by worsening malnutrition [6]. Helminth infections are
characterised by a strong Th2 response [7] and it has been suggested that this might suppress a
protective Th1 response in VL patients and therefore contribute to the strong immunosuppres-
sion characteristic of these patients [8]. In addition, intestinal parasites may also contribute to
malnutrition by competing for nutrients in the gut, inducing chronic inflammation and causing
malabsorption. The Northwest of Ethiopia, where the current study took place, has a high preva-
lence of intestinal parasitic infections (both protozoa and helminths) [6] and malnutrition
appears to be relatively common [9]. However, precise information about the impact of co-
infection with intestinal parasites on the severity of patients with VL is scarce.
In the current study, we measured the impact of intestinal parasite co-infections on the dis-
ease status of patients with VL, before the start of anti-leishmanial treatment. Clinical data
were collected and haematological data, inflammatory mediators and cytokines were deter-
mined. All these parameters were compared between patients presenting with VL and VL
patients co-infected with intestinal parasites.
Methods
Subjects and sample collection
The study was approved by the Institutional Review Board of the University of Gondar (IRB,
reference SBMLS/1199/07). For this cross-sectional study, a cohort of 42 male non-endemic
Human visceral leishmaniasis and intestinal parasites
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healthy controls were recruited amongst the staff of Gondar University Hospital and 60 male
VL patients were recruited from the Leishmaniasis Research and Treatment Center of Gondar
University Hospital before treatment. All patients were male and migrant workers, and indeed
the large majority of VL patients at the Leishmaniasis Research and Treatment Center are
migrant workers. No women presented with visceral leishmaniasis during our study.
The exclusion criteria were age (<18 years), and co-infection with tuberculosis, malaria
and HIV. The diagnosis of VL was based on positive serology (rK39) and the presence of Leish-
mania amastigotes in spleen or bone marrow aspirates [10]. Written Informed consent was
obtained from each patient and control. Patients were treated with a combination of sodium
stibogluconate (20mg/kg body weight/day), and paromomycin (15mg/kg body weight/day)
injections, given intramuscularly for 17 days or with Ambisome1 (max of 30mg/kg body
weight, with 6 injections of 5mg/kg body weight /day) and showed an initial clinical cure rate
of 100% after treatment, defined as follows: at the end of successful treatment, patients look
improved, afebrile, and usually have a smaller spleen size than on admission and an improved
hematological profile.
The diagnosis of intestinal parasites was made in fresh stools, before the start of anti-leish-
manial treatment, collected in a clean screw top container. Part of the collected stool was pro-
cessed using the direct saline wet mount procedure [11, 12]; part was examined using the Kato-
katz technique [11, 12] and the rest was processed using the "formol ether concentration" tech-
nique [12]. All preparations were examined for the presence of parasites by microscopy, within
30 minutes after collection; each stool sample was examined by two experienced laboratory
technicians. Of note, only active intestinal infections were taken into account: Giardia and Ent-
amoeba cysts were observed in 3 and 5 patients, respectively, however, no trophozoites were
detected in their stools and therefore were not categorized as causing an active infection. Six ml
of blood was collected in EDTA tubes before the start of treatment and was processed within 10
minutes after collection: following density gradient centrifugation on Histopaque-1077 (Sigma),
the plasma was isolated from the top layer and frozen immediately. To count the percentages of
eosinophils, a drop of whole blood was smeared onto a glass slide, stained with Giemsa and the
percentages of eosinophils per 100 white blood cells were counted microscopically.
The BMI was measured as follows: Weight (kg)/ (height (m)) 2. Normal BMI was defined as
18.5, moderate malnutrition as BMI = 18.4–16.5 and severe malnutrition as BMI< 16.5.
Haematological analysis
The haematological profiles were determined by using an automated CELL-DYN1800 Haema-
tology Analyser, USA.
ELISA/Luminex
The ELISA for the determination of the acute phase C-reactive protein (CRP) was performed
as described in [13] (detection limit: 0.3μg/ml). ELISA kits were used for the determination of
IFN-γ, IL-6, IL-8 and IL-10 levels (Ready-SET-Go! ELISA Sets) in plasma, according to the
manufacturers’ protocol. The detection limits for these ELISA were 4pg/ml, 2pg/ml, 2pg/ml
and 32pg/ml, respectively. Elastase and Myeloperoxidase (BioVendor) were used according to
the manufacturers’ protocol. The detection limits for these ELISA were 0.2pg/ml and 0.4ng/
ml, respectively.
Cytokine analysis for interleukin (IL)-2, -4, -5, -12 and IL -13 was performed by using the
Luminex 200 system (USA, Multiplex Map Kit) and the plate was analyzed using the Luminex
100 system. The detection limits for these tests were 2.5pg/ml, 0.1pg/ml, 3.1 pg/ml, 2.5pg/ml
and 3pg/ml, respectively.
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Arginase activity
The enzymatic activity of arginase in the plasma was measured as previously described [14].
Briefly, urea concentrations were first determined without the activation and hydrolysis steps;
these values were subtracted from those obtained by measuring the urea levels. One unit of
enzyme activity is defined as the amount of enzyme that catalyzes the formation of 1 μmol of
urea per min.
Statistical analysis
Data were evaluated for statistical differences using two-tailed Mann-Whitney (GraphPad
Prism 6) and differences were considered statistically significant at p<0.05. Results are
expressed as median± SEM.
Results
Clinical data
Sixty male VL patients were recruited into our study and their clinical data are summarized in
Table 1. Their intestinal parasite (IP) status was determined and as shown in Table 2: 48.3%
(29 patients = IP+) were positive for intestinal parasites: 18 VL patients were co-infected with
hookworms, 8 with Ascaris (A.) lumbricoides, 4 with Schistosoma(S.) mansoni, 2 with Ent-
amoeba (E.) histolytica, 1 with Trichuris(T.) trichiura, and 1 with Strongyloides (S.) stercoralis.
Of note, both S. mansoni and S. haematobium are prevalent in Ethiopia, mainly in school-age
children [15, 16], but since our aim was to study the impact of intestinal parasites on VL dis-
ease severity, we focus on S. mansoni. Out of the 29 VL patients co-infected with intestinal
parasites, 5 patients were co-infected with 2 different intestinal parasites (Table 2). When strat-
ified according to their intestinal parasite (IP) status, the two groups were of similar age (IP+:
22.0±1.3 and IP-: 24.0±0.9, p>0.05); had a similar duration of illness (IP+: 8.0±0.8 and IP-:
6.0±1.0 weeks, p>0.05); similar parasite grade (spleen IP+: 3.0±0.2 and IP-: 3.0±0.3, p>0.05);
similar spleen size (IP+: 10.0±0.8 and IP-: 10.0±0.7, p>0.05) and liver size (IP+: 12.0±0.5 and
IP-: 3.5±0.4, p>0.05); and similar BMI (IP+: 17.4±0.3 and IP-: 17.2±0.3, p>0.05) (Table 1 and
Fig 1).
We cannot exclude that we have underestimated strongyloidiasis due to the sensitivity of
diagnostic tests based on parasitological examination, however, we did not have access to PCR
or serological tests.
30.4% of the VL patients IP+ and 22.7% of VL patients IP- presented with diarrhoea.
Importantly, co-infection with intestinal parasites did not affect the treatment of VL patients,
as all 29 IP+ VL patients were successfully treated in the same time frame and had a positive
initial clinical cure.
Haematological data
Next, we assessed the haematological profile of the 2 cohorts of patients and as shown in
Table 3 and Fig 2, VL patients presented with severe pancytopenia, and anaemia, as compared
to healthy non-endemic controls (S1 Table). No significant differences (p>0.05) were observed
in neutrophil, white blood cell (WBC) and platelet (Plt) counts, haemoglobin (Hgb) and hae-
matocrit (Hct) between VL patients and VL patients co-infected with IP. The percentages of
eosinophils in whole blood was low (<3) or undetectable in both groups, therefore no statisti-
cal differences could be evaluated.
Human visceral leishmaniasis and intestinal parasites
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Table 1. Clinical data.
Patient Age Duration of illness (weeks) Parasite grade (spleen) Parasite grade
(bone marrow)
Spleen size
(cm)
Liver size
(cm)
BMI
1 22 12 1 6 11 15.2
2 25 8 5 10 13 16
3 22 4 3 15 15 15.2
4 35 4 1 12 12 20.4
5 43 4 1 15 12 18.2
6 50 8 4 10 13 14.7
7 26 12 1 6 12 16.8
8 22 8 2 7 13 17.3
9 18 12 2 11 16 15.2
10 30 6 2 9 12 17.8
11 21 16 4 11 15 15.2
12 23 8 1 not palpable 14 17.6
13 20 4 1 7 12 14.4
14 28 12 3 8 12 16.3
15 28 4 3 13 14 16.2
16 19 4 2 18 13 16.3
17 28 4 1 7 13 17.3
18 20 8 1 7 9 16.6
19 28 8 4 15 10 18.6
20 28 8 3 6 12 14
21 20 4 1 14 13 19.2
22 26 8 3 not done not done 17.2
23 18 3 3 3 not done 17.4
24 30 2 2 not done not done 18
25 24 2 3 6 not done 17.2
26 32 4 3 6 not palpable 17.5
27 19 not done 3 10 not done 17.6
28 19 12 3 7 15 12.9
29 24 4 3 8 14 20
30 20 4 6 12 14 17.3
31 23 12 3 7 14 15.4
32 18 12 3 9 14 17.2
33 20 4 5 12 14 17.3
34 22 12 4 8 11 15.6
35 22 2 1 10 13 16.4
36 22 8 2 16 12 17.4
37 23 12 2 5 14 18.7
38 18 8 2 5 10 14.1
39 20 3 5 11 12 16.3
40 25 4 3 4 13 15.6
41 26 4 1 19 12 19.5
42 20 8 1 12 11 18.8
43 24 28 1 11 19 18.1
44 40 4 3 11 8 15
45 22 4 2 13 6 14.9
46 22 4 2 4 12 19.7
(Continued )
Human visceral leishmaniasis and intestinal parasites
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005727 July 21, 2017 5 / 16
Inflammatory response
VL is characterized by a strong systemic inflammation as measured by high levels of inflamma-
tory cytokines in the plasma of these patients [8]. To assess whether co-infection of VL patients
with IP had an impact on the systemic inflammation, the levels of CRP, IL-6 and IL-8 were
measured in the plasma of the two groups of VL patients. The results confirm the strong in-
flammatory status, and as shown in Table 4 and Fig 3, no significant differences were observed.
We also assessed the levels of arginase, myeloperoxidase and elastase in the plasma of the two
groups of VL patients; these enzymes are all found in primary granules of neutrophils, which
are the last granules to be released following activation of neutrophils. Results presented in
Table 4 and Fig 3 show that the levels of these enzymes were similar in the plasma of the two
groups of VL patients.
Th1, Th2 and regulatory cytokines
VL infections in human are characterised by high levels of IL-10 and IFN-γ [17]. To assess
whether co-infection of VL patients with IP affects the systemic cytokine profile, we measured
by Luminex and ELISA an array of different cytokines. Our results show that the Th1 (Table 5),
Th2 (Table 6) and IL-10 (Table 7) cytokine profiles were similar in the plasma of both groups of
VL patients.
Discussion
Our results show that the clinical and haematological data, inflammatory markers, cytokine
profiles and BMI are similar in VL patients co-infected with intestinal parasites and VL
patients with no intestinal parasites. The logistic regression model was used to test the associa-
tion of IL-10, IL-8, IFN-γ, Plt, HCT, Hgb, WBC and BMI with IP. The IP variable was defined
as positive response for at least one variable presented in Table 2. Due to low frequency of
infections for the variables T. trichiura, E. histolytica and S. stercoralis (the last three variables
Table 1. (Continued)
Patient Age Duration of illness (weeks) Parasite grade (spleen) Parasite grade
(bone marrow)
Spleen size
(cm)
Liver size
(cm)
BMI
47 21 8 3 4 12 15.2
48 32 4 1 4 13 17.6
49 22 3 2 15 13 18.4
50 21 16 3 6 12 19.4
51 28 8 4 13 15 17.7
52 25 6 not done 17 12 18.8
53 28 4 2 12 14 19.7
54 18 8 5 10 15 15
55 20 20 3 9 14 14.2
56 22 16 3 13 16 17.7
57 22 6 3 13 15 15.6
58 25 4 3 9 6 17.3
59 23 3 6 15 17 17.9
60 18 4 3 14 not done 15
Duration of illness is defined as the number of weeks since the patients noticed symptoms associated with visceral leishmaniasis, such as fever, and/or
enlarged abdomen (as a sign of enlarged spleen or liver).
https://doi.org/10.1371/journal.pntd.0005727.t001
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Table 2. Intestinal parasite distribution amongst VL patients.
Patients Hook worms S. mansoni A. lumbricoides T. Trichiura E. histolytica S. stercoralis
1 - - - - + -
2 - - - - - -
3 - - - - - -
4 - - - - - -
5 + - - - - -
6 + - - - - -
7 + + - - - -
8 - - - - - -
9 - - + - - -
10 - - - - - -
11 + - - - - -
12 + - - - - -
13 + - + - - -
14 - - - - - -
15 - - - - - -
16 - - - - - -
17 - - - - - -
18 - - - - - -
19 + - - - - -
20 - - - - - -
21 + - - - - -
22 - - - - - -
23 - - + - - -
24 - - - - - -
25 - - - - - -
26 - - - - + -
27 - + - - - -
28 - - - - - -
29 - - - - - -
30 - - - - - -
31 - + - - - -
32 - - - - - -
33 - - - - - -
34 - - - - - -
35 - + + - - -
36 + - - - - -
37 - - - - - -
38 - - + - - -
39 - - - - - -
40 + - - - - -
41 + - - - - -
42 + - - - - -
43 - - - - - -
44 - - - - - +
45 + - - - - -
46 + - - - -
47 - - + + - -
(Continued )
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Table 2. (Continued)
Patients Hook worms S. mansoni A. lumbricoides T. Trichiura E. histolytica S. stercoralis
48 - - - - - -
49 - - - - - -
50 - - + - - -
51 + - + - - -
52 - - - - - -
53 - - - - - -
54 - - - - - -
55 - - - - - -
56 + - - - - -
57 - - - - - -
58 + - - - - -
59 - - - - - -
60 + - - - - -
https://doi.org/10.1371/journal.pntd.0005727.t002
Fig 1. The age, duration of illness (defined as the number of weeks since the patients noticed symptoms associated with visceral
leishmaniasis, such as fever, and/or enlarged abdomen (as a sign of enlarged spleen or liver), parasite grades, spleen and liver sizes and BMI
was measured as described in Materials and Method in VL patients without intestinal parasite co-infections (IP-) and in VL patients co-infected
with intestinal parasites (IP+). Statistical significance was established using a Mann-Whitney test, ns = not significant (p<0.05).
https://doi.org/10.1371/journal.pntd.0005727.g001
Human visceral leishmaniasis and intestinal parasites
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reported in Table 2 with maximum number of infections of 1,2 and 2, respectively), co-infec-
tion patterns were investigated for hookworms, S. mansoni and A. lumbricoides using Fisher
exact test (for the three possible pairs: hookworms and S. mansoni, hook worms and A. lumbri-
coides and S. mansoni and A. lumbricoides). In all cases it was found to be not significant.
All VL patients recruited at the LRTC presented with severe disease. Disease severity in
VL patients has been associated with hepatosplenomegaly, low BMI, pancytopenia, anaemia
and high parasite burden in splenic aspirates. Our results show hepatosplenomegaly in all but
one patient (these measurements were not taken in two patients); that the majority of the VL
patients were malnourished: 11 had a normal BMI (>18.5), 23 were moderately malnourished
(BMI 16.5–18.4) and 26 were severely malnourished (<16.5) and there was no significant dif-
ference in BMI between VL patients with and without co-infection with intestinal parasites. Of
note, we collected only one stool sample, however we maximised our chances to detect para-
sites by using three different techniques: direct saline wet mount, Kato-katz and "formol ether
concentration" techniques. Furthermore, the neutrophil and white blood cell counts of both
cohorts of VL patients were below the normal range. It is likely that the undetectable or very
low percentages of eosinophils are due to the severe pancytopenia characteristic of VL patients.
Finally, Leishmania parasites were present in the spleen or bone marrow aspirates of both
patient cohorts. The results showing that VL patients are malnourished are in agreement with
our previous results, showing that the large majority of VL patients are malnourished [18, 19].
Intestinal parasitic infections have long been associated with malnutrition in children [20, 21]:
clinical manifestations of intestinal parasitic infection range from acute or persistent diarrhoea
to dysentery, resulting in inflammation and nutrient malabsorption [22]. However, studies
about intestinal parasitic infections and malnutrition in adults are less common and some-
times conflicting. For example, a study performed in Brazil showed that hookworm infection
was associated with low BMI in adults [23]. But in a recent study performed in Ethiopia, the
prevalence of undernutrition was similar in individuals infected with or without intestinal par-
asite infections [24]. In line with these results we show that the BMI of VL patients co-infected
with IP were similar to those of VL patients. VL patients in the North West of Ethiopia are usu-
ally admitted with progressed, severe visceral leishmaniasis and since undernutrition and
therefore a low BMI is characteristic of acute disease in patients with VL, [18, 19], any impact
Table 3. Comparison of complete blood count.
IP- IP+ p values
Neutrophils (x103)/μl 0.7±0.1 1.1±0.1 0.2300
WBC (x103)/μl 2.1±0.3 2.1±0.2 0.5705
Plt (x103)/μl 53.0±9.5 73.0±6.2 0.2278
Hgb (g/dl) 7.0±0.4 8.2±0.4 0.4292
Hct (%) 24.5±1.2 25.8±1.3 0.4207
WBC = white blood cells
Plt = platelets
Hct = haematocrit
Hb = haemoglobin.
Normal range: neutrophils (x103)/μl = 2–7.5; platelets (x103)/μl = 150–450; white blood cells (x103)/μl = 4.5–
10.5; Hct (%) = 35–60; Hgb (g/dl) = 11–18.
These parameters were measured in the blood of VL patients without intestinal parasite co-infection (IP-)
and in VL patients co-infected with intestinal parasites (IP+), using a CELL-DYN 1800 Haematology
Analyser, USA.
Statistical significance was established using a Mann-Whitney test.
https://doi.org/10.1371/journal.pntd.0005727.t003
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of intestinal parasite-related malnutrition might be hidden by the extent of malnutrition due
to VL. Our results are in disagreement with those by Mengesha et al. [25], which show that VL
patients were more likely to be severely malnourished when co-infected with IP. There are
important differences between the recruitment of patients between our study and that of Men-
gesha et al., as we excluded other co-infection, such as TB, malaria and most importantly HIV;
and indeed, we had previously shown that the BMI of HIV/VL patients was even lower as the
Fig 2. WBC = white blood cells; Plt = platelets; Hct = hematocrit; Hb = haemoglobin. Normal range: neutrophils (x103)/μl = 2–7.5, platelets (x103)/
μl = 150–450; white blood cells (x103)/μl = 4.5–10.5; Hct (%) = 35–60; hb (g/dl) = 11–18,Neutrophil (x103) These parameters were measured in the blood of
VL patients without intestinal parasite co-infections (IP-) and in VL patients co-infected with intestinal parasites (IP+), using a CELL-DYN 1800 Haematology
Analyser, USA. Statistical significance was established using a Mann-Whitney test, ns = not significant (p<0.05).
https://doi.org/10.1371/journal.pntd.0005727.g002
Table 4. Comparison of inflammatory markers.
IP- IP+ p values
CRP (μg/ml) 25.5±8.7 41.0±15.5 0.1736
IL-6 (pg/ml) 30.1±23.7 14.1±25.1 0.1715
IL-8 (pg/ml) 10.8±2.7 15.6±2.7 0.9942
Arginase (mU/ml) 19.1±3.0 22.1±3.8 0.9929
Myeloperoxidase (ng/ml) 208.5±102.7 212.5±55.1 0.6627
Elastase (pg/ml) 34.6±7.1 15.4±11.6 0.5578
The levels of CRP, IL-6, IL-8, myeloperoxidase and elastase were measured by ELISA and the levels of arginase activities by enzymatic assay, as
described in Materials and Methods, in the plasma from VL patients without intestinal parasite co-infection (IP-) and in VL patients co-infected with intestinal
parasites (IP+).
Statistical significance was established using a Mann-Whitney test.
https://doi.org/10.1371/journal.pntd.0005727.t004
Human visceral leishmaniasis and intestinal parasites
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BMI of VL patients [18]. In addition, we only considered patients with active intestinal para-
sitic infections, i.e. for example, patients with cysts of Giardia or Entamoeba, but no trophozo-
ites, were excluded from our study. We did not find any significant differences in the median
age, duration of illness, size of the spleen or liver and parasite grade in the spleen. Of note, in
contrast to VL patients, none of the VL patients co-infected with IP had a maximum parasite
grade of 5+ or 6+; however, the numbers of patients with high parasite burden are too low to
make a significant conclusion. All the haematological data measured in the two groups were
also similar and characteristic of VL patients [19].
VL is associated with high levels of systemic inflammation [8]. We have recently shown that
neutrophils, which are major players in the induction and maintenance of inflammation, are
highly activated and have degranulated, as shown by increased levels of arginase, myeloperoxi-
dase and elastase in the plasma of VL patients [26]. These results suggested that the elevated
Fig 3. The plasma from VL patients without intestinal parasite co-infections (IP-) and in VL patients co-infected with intestinal parasites (IP+)
was tested by ELISA (CRP, IL-6, IL-8, myeloperoxidase and elastase) or enzymatic activity (arginase) as described in Materials and Methods.
Statistical significance was established using a Mann-Whitney test, ns = not significant (p<0.05).
https://doi.org/10.1371/journal.pntd.0005727.g003
Table 5. Comparison of Th1 cytokine levels.
IP- IP+ p values
IFN-γ (pg/ml) 433.0±107.1 774±125.7 0.1748
IL-2 (pg/ml) 0.0±4.3 0.0±1.6 0.5898
IL-12 (pg/ml) 0.8±0.9 0.1±15.7 0.5083
The levels of IFN-γ were measured by ELISA and the levels of IL-2 and IL-12 were measured by Luminex,
as described in Materials and Methods, in the plasma from VL patients without intestinal parasite co-
infection (IP-) and in VL patients co-infected with intestinal parasites (IP+).
Statistical significance was established using a Mann-Whitney test.
https://doi.org/10.1371/journal.pntd.0005727.t005
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levels of arginase, MPO and elastase are markers of a severe and systemic inflammatory
response that is at least in part caused by high neutrophil activation. In our two cohorts of IP
+ and IP- VL patients, the levels of arginase activity, myeloperoxidase and elastase were com-
parable. Furthermore, in addition to their potential role as markers of inflammation, these
enzymes could also exacerbate immunopathological processes and therefore disease severity:
arginase has been shown to play a role in T cell suppression [19] and in Leishmania parasite
replication [14]; and both myeloperoxidase and elastase have the potential to affect parasite
survival [27–29]. However, our results suggest that co-infection of VL patients with intestinal
parasites does not impact on the levels of these three enzymes in the plasma.
Since parasitic infections are associated with an increased Th2-type response, we antici-
pated that the Th2 cytokines might be increased in VL patients co-infected with IP and that
this might affect inflammation, but as shown by the similar levels of inflammatory mediators,
the levels of inflammation are not altered in VL patients co-infected with IP; and indeed the
levels of IL-5 were similar and those of IL-4 and IL-13 were below the detection limits of the
ELISA we used.
In contrast to experimental models of leishmaniasis [30], the cytokine profile in VL patients
is not associated with a Th1 or Th2 type cytokine profile. Indeed, high levels of both IL-10 and
IFN-γ in the plasma are a hallmark of VL patients [17], IL-4 has been shown to be increased in
VL patients [31], but only minimally [32] or even undetectable [33] in other studies. In line
with the parameters we measured in the two groups of patients, the cytokine profiles of VL
patients co-infected with IP are similar to that of VL patients.
The lack of apparent differences in the parameters we measured between the two groups of
patients is likely to be due to the severity of VL, which might mask any differences that might
be driven by the presence of intestinal parasites. Indeed, our previous study has shown that VL
is severe in patients admitted to the Leishmania Research and Treatment Center in Gondar, as
the duration of illness was considerably longer in the patients from the North West of Ethiopia
as compared to those from Bihar, in India [34]; and that all patients presented with hepatosple-
nomegaly, low BMI, pancytopenia, anaemia and high parasite burden in splenic aspirates.
Table 6. Comparison of Th2 cytokine levels.
IP- IP+ p values
IL-4 (pg/ml) Not detectable Not detectable Not applicable
IL-5 (pg/ml) 1.4±3.1 1.3±1.9 0.5086
IL-13 (pg/ml) Not detectable Not detectable Not applicable
The levels of IL-4, IL-5 and IL-13 were measured by Luminex, as described in Materials and Methods, in the
plasma from VL patients without intestinal parasite co-infection (IP-) and in VL patients co-infected with
intestinal parasites (IP+).
Statistical significance was established using a Mann-Whitney test.
https://doi.org/10.1371/journal.pntd.0005727.t006
Table 7. Comparison of IL-10 levels.
IP- IP+ p values
IL-10 (pg/ml) 287.1±38.4 241.1±21.2 0.2274
The levels of IL-10 were measured by ELISA, as described in Materials and Methods, in the plasma from VL
patients without intestinal parasite co-infection (IP-) and in VL patients co-infected with intestinal parasites
(IP+).
Statistical significance was established using a Mann-Whitney test.
https://doi.org/10.1371/journal.pntd.0005727.t007
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Further studies would benefit from a better characterization of the intestinal parasites in VL
patients by using additional techniques, such as PCR, serological tests, as well as quantification
of the load of each parasite and the collection of three consecutive samples.
In summary, our results show that co-infection of VL patients with IP does not affect VL
disease severity, since clinical, haematological data and the treatment outcome are not altered
by co-infection; in addition, none of the immunological markers we measured were different.
However, in the light of the continuing debate about deworming [35], these results should be
taken with care; our cohort of VL patients suffer from a highly debilitating disease, that is fatal
if left untreated, and it might be therefore difficult to accurately dissect the contribution of a
less severe disease, such as soil transmitted helminths. Notably, we did not address the medical
conditions of these patients during follow-up, and whereas the relapse rate of VL patients is
low [36] in this setting, we cannot exclude that these relapses might be linked to the presence
of intestinal parasites. Interestingly, one recent study show that intestinal helminth infections,
but not protozoan parasites, had a deleterious impact on the clinical course of cutaneous leish-
maniasis (CL) caused by Leishmania braziliensis, as shown by increased frequency of mucosal
lesions, poorer and longer response to therapy in co-infected CL patients [37]. Importantly,
more work is needed to determine whether infection with an intestinal parasite prior to
acquiring Leishmania parasites might lead to increased risks of developing leishmaniasis.
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